You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

myeloid neoplasms

Showing 1 - 25 of 4,278
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

The Myeloid Neoplasms Biology and Outcome Project

Recruiting
  • Myeloid Neoplasm
    • Heidelberg, Baden-Württemberg, Germany
      UHHeidelberg
    Nov 21, 2022

    Myeloid Tumor Trial in Memphis (CPX-351, MHA)

    Recruiting
    • Myeloid Neoplasm
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    Jan 20, 2023

    Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory

    Recruiting
    • Relapsed or Refractory Acute Myeloid Leukemia
    • +2 more
    • Duarte, California
    • +1 more
    Mar 14, 2023

    Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Baltimore, Boston, Columbus (Enasidenib)

    Active, not recruiting
    • Acute Myeloid Leukemia
    • Chronic Myelomonocytic Leukemia
    • Baltimore, Maryland
    • +3 more
    Aug 8, 2022

    Acute Myeloid Leukemia, Myeloid Tumor Trial in Seattle (Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • Myeloid Neoplasm
    • Biospecimen Collection
    • +9 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Sep 5, 2023

    Myeloid Malignancy, MDS, Myelofibrosis Trial in Boston (Navitoclax, Venetoclax, Decitabine)

    Recruiting
    • Myeloid Malignancy
    • +4 more
    • Boston, Massachusetts
    • +2 more
    Jul 21, 2022

    Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia Trial in Seattle (Cladribine, Cytarabine,

    Recruiting
    • Acute Biphenotypic Leukemia
    • +11 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Oct 18, 2022

    Intervention Trial in Rochester (GO-EXCAP Mobile App)

    Completed
    • Intervention
    • GO-EXCAP Mobile App
    • Rochester, New York
      University of Rochester Medical Center
    Dec 7, 2021

    Cancer, Myeloid Tumor Trial in Rochester (GO-EXCAP Mobile App, Behavioral Placebo Control)

    Recruiting
    • Cancer
    • Myeloid Neoplasm
    • GO-EXCAP Mobile App
    • Behavioral Placebo Control
    • Rochester, New York
      University of Rochester Medical Center/Wilmot Cancer Institute
    Jan 4, 2022

    AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

    Not yet recruiting
    • AML
    • +11 more
    • (no location specified)
    Aug 14, 2023

    IDH1 Mutation Myeloid Tumors Trial in Baltimore, Boston, Columbus (Ivosidenib)

    Active, not recruiting
    • IDH1 Mutation Myeloid Neoplasms
    • Baltimore, Maryland
    • +3 more
    Oct 25, 2021

    MDS, Chronic Myelomonocytic Leukemia, Stem Cell Leukemia Trial in Boston (Inqovi)

    Recruiting
    • Myelodysplastic Syndromes
    • +2 more
    • Boston, Massachusetts
      Massachusetts General Hospital
    Sep 29, 2021

    Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted

    Recruiting
    • Acute Myeloid Leukemia
    • +3 more
    • CD123 targeted CAR-NK cells
    • Taiyuan, Shanxi, China
      Shanxi Bethune Hospital
    Aug 28, 2023

    Myeloproliferative Tumor, Secondary Leukemia Trial (Multiomic characterization, In vitro drug screening)

    Not yet recruiting
    • Myeloproliferative Neoplasm
    • Secondary Leukemia
    • Multiomic characterization
    • In vitro drug screening
    • (no location specified)
    Aug 28, 2023

    Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Tumor Trial in United States (APR-246, Azacitidine)

    Completed
    Has Results
    • Myelodysplastic Syndrome
    • +3 more
    • Tampa, Florida
    • +5 more
    Jan 14, 2022

    Myeloid Malignancy, Acute Myeloid Leukemia, MDS Trial in Rochester (Telehealth Serious Illness Care Program, Education Control)

    Not yet recruiting
    • Myeloid Malignancy
    • +4 more
    • Telehealth Serious Illness Care Program
    • Education Control
    • Rochester, New York
      University of Rochester
    May 24, 2023

    Myeloid Malignancies Trial in Chendu (fractionated busulfan-based conditioning regimen)

    Recruiting
    • Myeloid Malignancies
    • fractionated busulfan-based conditioning regimen
    • Chendu, Sichuan, China
      West China Hospital, Sichuan University
    Mar 29, 2023

    Myeloid Malignancy, Acute Myeloid Leukemia Trial in Cleveland (Venetoclax, Decitabine)

    Not yet recruiting
    • Myeloid Malignancy
    • Acute Myeloid Leukemia
    • Cleveland, Ohio
      University Hospitals Seidman Cancer, Case Comprehensive Cancer C
    Nov 8, 2023

    Acute Myeloid Leukemia, MDS, Myeloid Malignancies Trial in Boston (Decitabine, Filgrastim)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • +6 more
    • Boston, Massachusetts
    • +1 more
    Mar 31, 2023

    Hypomethylating Agent, Venetoclax, Myeloid Malignancy Trial in Shanghai (Venetoclax, Azacitidine or decitabine)

    Recruiting
    • Hypomethylating Agent
    • +2 more
    • Shanghai, Shanghai, China
      Shanghai Jiao Tong University School of Medicine Affilated Shang
    May 2, 2023

    Leukemia, Myeloid, Acute, MDS, Hematopoietic Stem Cell Transplantation Trial in Shanghai (Venetoclax plus RIC)

    Not yet recruiting
    • Leukemia, Myeloid, Acute
    • +3 more
    • Venetoclax plus RIC
    • Shanghai, Shanghai, China
      Shanghai General Hospital
    Oct 12, 2022

    Acute Myeloid Leukemia, Myeloproliferative Tumor, Myelodysplastic/Myeloproliferative Tumor Trial in Canada, United States

    Recruiting
    • Acute Myeloid Leukemia
    • +2 more
    • Birmingham, Alabama
    • +9 more
    Aug 30, 2021

    Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Houston (Cyclophosphamide, Mesna, Filgrastim)

    Recruiting
    • Myeloid Malignancies
    • +3 more
    • Houston, Texas
      M D Anderson Caner Center
    Nov 17, 2022

    Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells,

    Completed
    Has Results
    • Blasts More Than 20 Percent of Bone Marrow Nucleated Cells
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 18, 2022

    Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms

    Not yet recruiting
    • Pyruvate Kinase Deficiency
    • +10 more
    • Blood Draw
    • Boston, Massachusetts
      Massachusetts General Hospital
    May 21, 2021